Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

laboratoires thea - desametasone - desametasone

Italia - italiano - Ministero della Salute

vetoquinol sa - clotrimazolo, desametasone, marbofloxacina - marbofloxacina - 3 mg; clotrimazolo - 10 mg; desametasone - nd, clotrimazolo - 10 mg; desametasone - 0.9 mg; marbofloxacina - 3 mg - dexamethasone and antiinfectives

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

helvepharm ag - lenalidomidum - capsule rigide - lenalidomidum 2.5 mg, cellulosum microcristallinum, lactosum 33.2 mg, carmellosum natricum conexum corresp. natrium 0.089 mg, magnesii stearas, kapselhülle: gelatina, titanii dioxidum, e 172 (flavum), e 132, drucktinte: lacca, e 172 (nigrum), propylenglycolum, kalii hydroxidum, pro capsula. - onkologikum - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

helvepharm ag - lenalidomidum - capsule rigide - lenalidomidum 5 mg, cellulosum microcristallinum, lactosum 66.4 mg, carmellosum natricum conexum corresp. natrium 0.178 mg, magnesii stearas, kapselhülle: gelatina, titanii dioxidum, drucktinte: lacca, e 172 (nigrum), propylenglycolum, kalii hydroxidum, pro capsula. - onkologikum - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

helvepharm ag - lenalidomidum - capsule rigide - lenalidomidum 7.5 mg, cellulosum microcristallinum, lactosum 99.7 mg, carmellosum natricum conexum corresp. natrium 0.266 mg, magnesii stearas, kapselhülle: gelatina, titanii dioxidum, e 172 (flavum), drucktinte: lacca, e 172 (nigrum), propylenglycolum, kalii hydroxidum, pro capsula. - onkologikum - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

helvepharm ag - lenalidomidum - capsule rigide - lenalidomidum 10 mg, cellulosum microcristallinum, lactosum 132.9 mg, carmellosum natricum conexum corresp. natrium 0.355 mg, magnesii stearas, kapselhülle: gelatina, titanii dioxidum, e 172 (flavum), e 132, drucktinte: lacca, e 172 (nigrum), propylenglycolum, kalii hydroxidum, pro capsula. - onkologikum - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

helvepharm ag - lenalidomidum - capsule rigide - lenalidomidum 15 mg, cellulosum microcristallinum, lactosum 199.3 mg, carmellosum natricum conexum corresp. natrium 0.539 mg, magnesii stearas, kapselhülle: gelatina, titanii dioxidum, e 132, drucktinte: lacca, e 172 (nigrum), propylenglycolum, kalii hydroxidum, pro capsula. - onkologikum - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

helvepharm ag - lenalidomidum - capsule rigide - lenalidomidum 20 mg, cellulosum microcristallinum, lactosum 265.8 mg, carmellosum natricum conexum corresp. natrium 0.716 mg, magnesii stearas, kapselhülle: gelatina, titanii dioxidum, e 172 (flavum), e 132, drucktinte: lacca, e 172 (nigrum), propylenglycolum, kalii hydroxidum, pro capsula. - onkologikum - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

helvepharm ag - lenalidomidum - capsule rigide - lenalidomidum 25 mg, cellulosum microcristallinum, lactosum 332.2 mg, carmellosum natricum conexum corresp. natrium 0.894 mg, magnesii stearas, kapselhülle: gelatina, titanii dioxidum, drucktinte: lacca, e 172 (nigrum), propylenglycolum, kalii hydroxidum, pro capsula. - onkologikum - synthetika

Unione Europea - italiano - EMA (European Medicines Agency)

krka, d.d., novo mesto  - lenalidomide hydrochloride monohydrate - multiple myeloma; lymphoma, follicular - immunosoppressori - multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) è indicato per il trattamento di pazienti adulti con mieloma multiplo precedentemente non trattato e che non sono idonei per il trapianto. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) è indicato per il trattamento di pazienti adulti con mieloma multiplo precedentemente non trattato e che non sono idonei per il trapianto. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).